KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Return on Sales (2016 - 2025)

Jazz Pharmaceuticals has reported Return on Sales over the past 16 years, most recently at 0.17% for Q4 2025.

  • Quarterly results put Return on Sales at 0.17% for Q4 2025, down 1.0% from a year ago — trailing twelve months through Dec 2025 was 0.08% (down 22.0% YoY), and the annual figure for FY2025 was 0.08%, down 22.0%.
  • Return on Sales for Q4 2025 was 0.17% at Jazz Pharmaceuticals, down from 0.22% in the prior quarter.
  • Over the last five years, Return on Sales for JAZZ hit a ceiling of 0.22% in Q3 2025 and a floor of 0.69% in Q2 2025.
  • Median Return on Sales over the past 5 years was 0.09% (2023), compared with a mean of 0.01%.
  • Biggest five-year swings in Return on Sales: skyrocketed 52bps in 2022 and later crashed -85bps in 2025.
  • Jazz Pharmaceuticals' Return on Sales stood at 0.04% in 2021, then crashed by -584bps to 0.25% in 2022, then surged by 138bps to 0.09% in 2023, then surged by 88bps to 0.18% in 2024, then decreased by -3bps to 0.17% in 2025.
  • The last three reported values for Return on Sales were 0.17% (Q4 2025), 0.22% (Q3 2025), and 0.69% (Q2 2025) per Business Quant data.